RTP Mobile Logo

Sunday, March 25, 2018, New Orleans, LA, 6:30 AM – 7:30 AM

New Agents and Emerging Strategies in the Management of Uterine Sarcomas

An Independent CME Satellite Symposium During the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

Event Details

Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 613-3933

Event Time (Central Time):
6:00 AM – 6:30 AM — Registration and Breakfast Buffet
6:30 AM – 7:30 AM — Educational Meeting

Meeting Room:
Empire Ballroom A (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Suzanne George, MD
Clinical Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Martee L Hensley, MD
Attending, Gynecologic Medical Oncology
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

David M O'Malley, MD
Director, Clinical Research Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC-James
The Ohio State University and The James Cancer Center
Columbus, Ohio

Neil Love, MD
Research To Practice
Miami, Florida


MODULE 1: Clinical Decision-Making for Patients with Localized Uterine Leiomyosarcoma (uLMS) — Dr O’Malley

Faculty Case Presentation

Faculty Presentation Topics

  • Multidisciplinary considerations in the management of localized uLMS or other uterine sarcoma subtypes
  • Indications for the use of adjuvant radiation therapy (RT) and/or cytotoxic therapy for patients with early-stage uLMS; available efficacy data
  • Selection of agent/regimen in patients receiving adjuvant systemic therapy
  • Rates of ER/PR positivity in uLMS; available data with aromatase inhibition in patients with early-stage uLMS
  • What specific clinical or pathologic features (eg, age, tumor size, histology, lymphatic involvement) should be evaluated by the treatment team to help estimate prognosis for these patients?
  • In what clinical situations do you offer adjuvant RT to your patients with localized uLMS? What is known about the contribution of RT (with and without chemotherapy) to long-term outcomes in these individuals?
  • In general, what specific postoperative imaging studies or other surveillance strategies do you employ to monitor for the presence of metastases?
  • Given the high recurrence rates observed in patients with early-stage uLMS, what other innovative therapeutic strategies are being evaluated in clinical trials that you might encourage a patient to consider?

MODULE 2: Current Front-Line Management of Metastatic uLMS — Dr Hensley

Faculty Case Presentation

Faculty Presentation Topics

  • Guideline-endorsed first-line therapeutic options for patients with metastatic uLMS or other histologic subtypes
  • Results from the GeDDis trial evaluating gemcitabine/docetaxel versus doxorubicin monotherapy in patients with advanced uterine sarcomas, including uLMS
  • Mechanism of action of olaratumab; rates and prognostic significance of platelet-derived growth factor alpha (PDGFRα) overexpression among patients with various soft tissue sarcomas (STS), including uLMS
  • Design, eligibility criteria and efficacy outcomes of the randomized Phase II JGDG trial of olaratumab/doxorubicin versus doxorubicin alone for patients with STS, including uLMS
  • Patient selection for and practical integration (eg, dosing, side-effect management) of olaratumab into clinical practice
  • Ongoing Phase III ANNOUNCE trial of doxorubicin versus doxorubicin/olaratumab in patients with advanced or metastatic STS
  • For patients with recurrent disease, does the specific agent/regimen used in the adjuvant setting affect your selection of subsequent therapy?
  • For which patients with Stage IV disease, if any, do you consider single-agent doxorubicin versus combination therapy in the up-front setting? When you do elect to use combination therapy for a patient with metastatic disease, which first-line regimen do you generally recommend?
  • Is there any correlation between the level of PDGFRα expression and response to olaratumab? Given what we know about the risks and benefits of olaratumab, do you believe it should be investigated as a “maintenance” strategy for patients with gynecologic sarcomas?
  • Would you feel comfortable combining olaratumab with any other chemotherapy backbone beyond doxorubicin? Now that the drug is commercially available, are you still offering your patients participation in the randomized Phase III ANNOUNCE trial? Why or why not?

MODULE 3: Protocol and Nonresearch Options for Patients with Recurrent/Refractory (R/R) uLMS in Later-Line Settings; Future Directions — Dr George

Faculty Case Presentation

Faculty Presentation Topics

  • Prospective and retrospective clinical trial data with trabectedin, pazopanib and eribulin mesylate and appropriate integration into nonreseach treatment algorithms
  • Available data with and ongoing investigation of immunotherapeutic strategies in uterine sarcomas
  • Genetic landscape of STS and potential role of next-generation sequencing to prioritize protocol and nonresearch treatment decision-making
  • Activity, ongoing evaluation and potential nonprotocol role, if any, of other commercially available anticancer agents in metastatic uLMS
  • What treatment would you generally recommend for a patient whose disease progresses after receipt of first-line olaratumab/doxorubicin? Are there any data to support the use of olaratumab (with a different chemotherapy) beyond disease progression in a patient with a significant response to up-front treatment?
  • How would you approach treatment for a patient who received gemcitabine/docetaxel as first-line therapy?
  • How do you generally sequence pazopanib and trabectedin for patients with R/R disease? Do you typically opt for one of these agents as second-line therapy, or do you prefer some other systemic approach (eg, single-agent or combination chemotherapy)? How might this decision change for a patient who is older or frail?
  • How, if at all, are you currently integrating eribulin into the care of your patients with metastatic uterine sarcomas? What is known about its use in patients with multiagent-refractory disease, and how does its effect vary by histologic subtype?
  • What is known about the use of anti-PD-1/PD-L1 antibodies either alone or in combination with other agents for patients with uterine sarcomas? Are there any situations in which you would currently attempt to administer a checkpoint inhibitor outside of a clinical trial for a patient with advanced uLMS?

CE Information

Target Audience:
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Appreciate the importance of multidisciplinary collaboration in the diagnosis and management of gynecologic sarcomas, and use this information to design a process to optimize tissue procurement, accurate histological assessment, tertiary care referral and treatment outcome.
  • Develop an evidence-based strategy for the treatment of Stage I to III uterine sarcoma, considering the potential contributions of surgery, radiation therapy and/or cytotoxic therapy.
  • Employ guideline-endorsed monitoring protocols and techniques to effectively screen patients with localized uterine leiomyosarcoma (uLMS) for the development of metastases.
  • Recognize the role platelet-derived growth factor receptor α (PDGFRα) expression plays in tumor proliferation and growth, and consider this information in the selection of therapeutic approach for patients with advanced uLMS.
  • Appraise available safety and efficacy data with approved targeted and cytotoxic therapies used in the treatment of advanced gynecologic sarcomas, and consider how these agents can be optimally incorporated into current clinical management algorithms.

CME Credit Form:
A credit form will be given to each participant at the conclusion of this activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by an educational grant from Lilly.


Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 613-3933

Meeting Room:
Empire Ballroom A (Level 2)

The Hyatt Regency New Orleans hotel is the main venue for the SGO Annual Meeting on Women's Cancer.



Thank you for your interest in our educational program. At this time online registration is closed. However, seats are still available for the meeting.

If you are interested in attending, please visit our onsite registration desk located outside the Empire Ballroom A (Level 2) of the Hyatt Regency New Orleans (601 Loyola Avenue). Our onsite registration desk will be open starting at 6:00 AM on Sunday, March 25, 2018.

We will accept new registrations on a first come, first served basis. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

Registration for this event is independent of registration for the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.